[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"migraine-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:migraine-disease":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,84,113,163,187,212],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643927","phase-1-a-prospective-open-label-study-evaluating-the-effectiveness-of-gepants-for-acute-treatment-of-migraine-in-the-emergency-department-100643927",false,"NCT07667621","A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department","A Prospective, Open-Label Study Evaluating the Effectiveness of Rimegepant ODT or Zavegepant Nasal Spray for Acute Treatment of Migraine in the Emergency Department","Inclusion Criteria:\n\n* • At least 18 years of age\n\n  * Capacity to provide informed consent (without a Representative)\n  * Emergency Department presentation for a headache consistent with migraine, based either on the treating clinical team's judgement, or fulfillment of International Classification of Headache Disorders (ICHD-3) criteria for migraine without aura or with typical aura, or for probable migraine without aura or with typical aura. It is acceptable if current headache duration is \\>72 hours. Must have been headache free for \\>48 hours prior to current attack.\n  * Willing to participate in post-discharge telephone assessments\n  * English and\u002For Spanish speaking patients\n\nExclusion Criteria:\n\n* • Use of intranasal decongestants within 1 hour prior to study drug administration, due to the potential to decrease absorption of intranasal zavegepant.\n\n  * Use of analgesics or abortive headache medications within 60 minutes of study medication administration\n  * Use of the following drug\u002Ffood categories with potential for drug interactions within 7 days or 5 half-lives, whichever is longer: 1) CYP3A strong or moderate inducers, 2) CYP3A4 strong inhibitors, 3) P-glycoprotein (P-gp) inhibitors, 4) OATP1B3 transporter potent inhibitors\u002Finducers, 5) NTCP transporter potent inhibitors\u002Finducers\n  * History of ischemic cardiovascular disease, diabetes, or hypertension (diagnosed or likely based on multiple readings), that was recently diagnosed within 3 months of screening or is currently uncontrolled or unstable\n  * History of any stroke within 3 months, or any lifetime stroke and age ≥65 years\n  * History of significant peripheral vascular disease, as assessed by the investigator or qualified delegate\n  * History of Raynaud's Phenomenon (medically diagnosed, or non-medically diagnosed with affirmative responses to both unusual sensitivity and finger color change with cold exposure)\n  * History of severe hepatic impairment, as assessed by the investigator or qualified delegate\n  * History of kidney disease stage 4 (eGFR \\\u003C30 mL\u002Fmin\u002F1.73 m2)\n  * History of hypersensitivity reaction to rimegepant, zavegepant, or to any included inactive ingredients\n  * Lifetime use of CGRP-targeting acute or preventive migraine medications\n  * In custody of law enforcement\n  * Current pregnancy or lactation\n\n    * All individuals of childbearing potential must have a negative pregnancy test at screening (urine or serum).\n    * A person is considered to be of childbearing potential if possessing female reproductive organs at birth, post-menarchal, has not reached a post-menopausal state (≥12 continuous months of amenorrhea with no cause identified other than menopause), and is not permanently infertile due to surgery (i.e., removal of ovaries, fallopian tubes, and uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis).",true,"ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","Prospective, single-site, open-label, non-controlled pilot study consisting of two parallel trials. Participants will receive rimegepant or zavegepant for acute migraine treatment during a single Emergency Department visit, with post-discharge follow-up through 28 days. Participants will be allocated to either the rimegepant trial or the zavegepant trial. The study design does not include a placebo or active comparator control group, and the two gepant study drugs are not designed to function as active comparator groups. The objective in this investigation is to examine relief from either rimegepant or zavegepant in separate parallel trials.",[27,28,29,30,31,32,33],"Migraine","Migraine Disease","Migraine in Adults","Migraine Headache","Acute Migraine","Migraine Without Aura","Migraine With Aura","NOT_YET_RECRUITING","2026-06-20",{"date":37,"type":38},"2026-06-25","ACTUAL",{"date":40,"type":21},"2026-07",{"date":42,"type":21},"2027-08",{"name":44,"class":45},"University of South Florida","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":65,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":46},"100643788","evaluation-of-the-migraceutics-phase-specific-dietary-supplement-regimen-on-quality-of-life-work-productivity-and-biomarkers-in-adult-migraineurs-the-migraceutics-start-study-100643788","NCT07634146","Evaluation of the Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study","A Randomized, Sham Supplement- and Care-as-Usual-Controlled Study to Evaluate Migraceutics® Phase-Specific Dietary Supplement Regimen on Quality of Life, Work Productivity, and Biomarkers in Adult Migraineurs: The Migraceutics® START Study","Inclusion Criteria:\n\n* Self-reported history of migraine, based on the International Headache Society (IHS) International Classification of Headache Disorders, 3rd edition (ICHD-3) diagnostic criteria for migraine.\n* Being able to take oral supplements.\n* Agreeing to maintain their regular lifestyle.\n* Access to internet and telephone.\n\nExclusion Criteria:\n\n* Pregnancy or lactation.\n* Presence of any active medical condition or diagnosis other than episodic migraine, including liver or kidney disease or condition.\n* Use of overlapping supplements or interacting medications.\n* Known allergies to study ingredients.\n* Daily use of alcohol, tobacco, or recreational drugs.\n* Participation in any other clinical or interventional study within 30 days prior to baseline or concurrently.","65 Years",{"count":56,"type":21},920,[58],"NA","The purpose of this study is to evaluate the impact of the Migraceutics® phase-specific dietary supplement regimen on quality of life, work productivity, and biomarkers in adult migraineurs.",[27,28,61,30,62,29,63,64],"Migraine Disorder","Migraine Disability","Menstrual Migraine","Menstrual Migraine (MM) Headaches",[66,67,68,69,70,71,72,73,74],"quality of life","productivity","disability","CGRP","headache","migraine","nutraceuticals","dietary supplement","migraceuticals","2026-06-03",{"date":77,"type":38},"2026-06-08",{"date":79,"type":21},"2026-07-08",{"date":81,"type":21},"2028-06-30",{"name":83,"class":45},"Miracle Wellness LLC",{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":90,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":92,"enrollmentInfo":93,"targetDuration":4,"studyType":22,"phases":95,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":104,"lastUpdatePostDateStruct":105,"startDateStruct":107,"completionDateStruct":109,"leadSponsor":111,"locationsCount":46},"100638428","phase-3-migraine-headaches-elimination-with-patent-foramen-ovale-directed-therapy-100638428","NCT07629635","Migraine Headaches Elimination With Patent Foramen Ovale-Directed Therapy","Cessation of Migraine Headaches With Patent Foramen Ovale-Directed Therapy (COMFORT - PFO): An Investigator-Initiated Study","COMFORT-PFO","Patient Inclusion Criteria:\n\n* Age: ≥18 and \\\u003C55 at time of screening\n* Migraine headache with aura, or migraine headache without aura, fulfilling conditions of the Neurology Screening Tool (meeting ICHD-3 criteria)\n* Diagnosis of migraine for ≥ 1 year; onset of migraine symptoms \\\u003C 40 years of age\n* By history, an average headache burden of greater than one migraine headache day per week:\n* without current preventative therapy, OR\n* despite preventative therapy, OR\n* with reason to come off effective therapy (e.g. cost, aversion to injections, side effects)\n* If patient is taking preventive migraine medications, dose must be stable for at least 3 months prior to the screening visit. Patient agrees to continue preventive medication at the current dosage throughout the duration of the Baseline and On-treatment monitoring periods (Study Weeks 1 - 17).\n* Female patients capable of becoming pregnant agree to use two forms of birth control or abstinence during their participation in the study.\n\nPatient Exclusion Criteria:\n\nExclusions due to underlying patient medical issues:\n\n* Headache disorder other than migraine with aura, or migraine without aura\n* Patient has history of stroke, TIA, or intracranial hemorrhage.\n* Patient has a history of thrombocytopenia within one year, or platelet count \\\u003C100,000\u002Fmm3 identified during the screening laboratory evaluation.\n* Patient has severe hepatic impairment with reduced synthetic function as documented by prolongation of PT\u002FPTT, or with total bilirubin \\>3.0 mg\u002FdL identified during the screening laboratory evaluation.\n* Patient has previously implanted pacemaker, IVC filter, PFO closure device, ASD closure device, or left atrial appendage closure device or any cardiac history which, in the investigator's opinion, would preclude them from study participation.\n* Patient has documented right-to-left shunt source in addition to PFO such as atrial septal defect or pulmonary arteriovenous malformation.\n* Patient has a history of clinically significant bleeding within 6 months of the screening visit, any active bleeding, or active peptic ulcer disease.\n* Patient has an uncontrolled arrhythmia, or if on therapy, has evidence of arrhythmia control failure within the past 90 days (e.g., supraventricular tachycardia or atrial fibrillation while under rhythm control).\n* Patient has elevated PVR which in the opinion of the implanting physician precludes safe PFO closure.\n* Patient has active infection at the time of screening that cannot be treated.\n* Patient is planning surgery during the study timeframe.\n* A female patient is pregnant or is planning pregnancy during the anticipated duration of the study. Urine or blood pregnancy screening will be performed as part of the screening laboratory evaluation.\n* Patient has documented nickel allergy\u002Fsensitivity\n* Patient has a documented history of non-compliance with medical care, which would preclude them, in the opinion of the study team\n\nExclusion Due to Medication Restrictions:\n\n* Patient has known hypersensitivity or contraindication to thienopyridines\n* Patient has another medical condition requiring chronic antithrombotic therapy with antiplatelet, oral anticoagulant or injectable agents\n* Patient has need for daily use of NSAIDs other than for treatment of migraines","55 Years",{"count":94,"type":21},32,[96],"PHASE3","Migraine is a common and often disabling condition, but its exact causes are not fully understood. Some people with migraines have a small opening in the heart wall called a patent foramen ovale (PFO). In some of these patients, closing this opening or taking a medication that inhibits blood platelets (prasugrel) has been shown to reduce migraines. However, not everyone benefits, and it is unclear why. This study is being done to better understand whether closing a PFO can provide lasting migraine relief - especially in patients whose migraines improve with prasugrel.\n\nThe goal of this study is to find out whether, in patients whose migraines improve while taking prasugrel, closing the PFO along with 24 weeks of prasugrel leads to better long-term migraine relief after stopping the medication, than by taking prasugrel for 24 weeks alone.\n\nParticipants will track their migraines daily using an electronic diary, then take prasugrel and compare their migraines while on the medication. Only patients whose migraines improve on this medication will continue in the study. Eligible participants will be randomly assigned (like flipping a coin) to one of two groups: 1) Medication-only group: Continue prasugrel for 24 weeks. 2) Procedure group: Undergo a minimally invasive procedure to close the PFO and continue prasugrel for 24 weeks. After treatment, the medication will be stopped in both groups, and participants will again track their migraines for about 8 weeks.\n\nThe main question is: Do patients who have PFO closure continue to have fewer migraines after stopping prasugrel compared with those who did not have the procedure?",[28,99],"Patent Foramen Ovale",[101,99,102,90,103],"Migraine Headaches","Thienopyridine","Prasugrel","2026-06-01",{"date":106,"type":38},"2026-06-05",{"date":108,"type":21},"2026-09-01",{"date":110,"type":21},"2028-03",{"name":112,"class":45},"Columbia University",{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":120,"minAge":18,"maxAge":121,"enrollmentInfo":122,"targetDuration":4,"studyType":22,"phases":123,"briefSummary":124,"conditions":125,"keywords":136,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100571149","aerobic-exercise-and-its-impact-on-sensory-musculoskeletal-and-psychosocial-aspects-in-migraine-100571149","NCT06716489","Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine","Influence of Aerobic Exercise on Sensory Perception, Musculoskeletal and Psychosocial Alterations in Patients With Migraine","Inclusion Criteria:\n\n* Women aged between 18 and 48 years.\n* Diagnosed with migraine by an experienced neurologist specialized in headaches, following the criteria of the International Classification of Headache Disorders (ICHD).\n* Frequency of headache between 3 and 8 days per month, to ensure adherence to the treatment.\n\nExclusion Criteria:\n\n* Presence of any other type of concurrent headache.\n* Medical conditions affecting sensitivity and autonomic modulation, such as peripheral neuropathies, autonomic disorders, severe neurological diseases, and others.\n* Conditions that prevent physical activity, such as severe musculoskeletal injuries, cardiovascular diseases, or related conditions.\n* Premature ovarian failure.\n* Regular physical exercise in the past year.\n* Body Mass Index (BMI) above 30.0.\n* Smokers or individuals using drugs that interfere with sensitivity and cardiac modulation (e.g., beta-blockers).\n* Abuse of abortive medications.","FEMALE","48 Years",{"count":20,"type":21},[58],"Migraine is a neurological disorder associated with high levels of disability and changes in sensory processing, musculoskeletal function, and psychosocial factors. Aerobic exercise is a low-cost, non-pharmacological strategy that has shown potential benefits for migraine management, but its effects on sensory perception and musculoskeletal function are not yet fully understood.\n\nThis randomized controlled trial will investigate the effects of a supervised aerobic exercise program combined with pain neuroscience education compared with an active control condition in women aged 18 to 48 years diagnosed with migraine. Participants will be randomly allocated to either an intervention group, which will perform supervised aerobic exercise three times per week for 16 weeks and receive one session of pain neuroscience education, or a control group, which will receive recommendations for unsupervised physical activity at home.\n\nOutcomes related to migraine-related disability, self-reported symptoms, sensory sensitivity, and musculoskeletal function will be assessed at baseline and after the intervention period. Questionnaires will also be collected at a 6-month follow-up. The results of this study may contribute to the development of accessible and low-risk non-pharmacological treatment strategies for people with migraine.",[27,28,61,126,127,128,129,130,131,132,133,134,135],"Migraine Disorders, Brain","Headache","Headache (Migraine)","Headache Disorders","Headache Disorders, Primary","Aerobic Exercise","Pain Management","Sensory Disorders","Psychosocial Factors","Quality of Life",[71,137,138,139,70,68,140,66,141,142,143,134,144,145,146,147,148,149,150,151,152],"aerobic exercise","sensory perception","exercise","musculoeskeletal alterations","neck pain","cervical pain","Sensory Thresholds","Physical Fitness","Exercise Intervention","Central Sensitization","Physical Therapy","Migraine Management","Non-pharmacological Treatment","Clinical Trial","Headache Relief","sensitization","RECRUITING","2026-04-27",{"date":156,"type":38},"2026-04-28",{"date":158,"type":38},"2026-03-03",{"date":160,"type":21},"2028-11-30",{"name":162,"class":45},"University of Sao Paulo",{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":167,"acronym":168,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":170,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":173,"conditions":174,"keywords":175,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":46},"100610927","neuropsychological-profile-characterization-in-patients-with-migraine-cognitive-functioning-and-psychological-variables-100610927","NCT07233941","Neuropsychological Profile Characterization in Patients With Migraine: Cognitive Functioning and Psychological Variables","CogMIG","Inclusion Criteria:\n\n* Written informed consent.\n* Patients aged between 18 and 65 years.\n* Diagnosis of migraine according to the International Classification of Headache Disorders (ICHD-3) criteria.\n* Patients with a history of migraine for at least one year, to ensure the stability of the condition.\n* Stability of ongoing treatment for at least 3 months at baseline.\n* Understanding of the Italian language.\n\nExclusion Criteria:\n\n* Severe medical or psychiatric conditions (depression, schizophrenia, psychosis) documented by specific previous diagnoses.\n* A history of alcohol or drug abuse.\n* Primary sensory deficits.",{"count":171,"type":21},150,"OBSERVATIONAL","The overall objective is to define the neuropsychological profile of patients with migraine and evaluate its association with: psychological outcome measures (anxiety-depressive symptoms, pain catastrophizing, excessive worry, and coping strategies); the clinical profile of migraine; the prodromal, ictal, or interictal phase of the migraine attack; pharmacological therapy; and detoxification treatment in patients with migraine associated with medication overuse headache.",[27,28],[71,176,177],"cognition","cognitive impairment","2026-02-09",{"date":180,"type":38},"2026-02-11",{"date":182,"type":38},"2025-09-01",{"date":184,"type":21},"2027-05",{"name":186,"class":45},"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta",{"id":188,"slug":189,"hasResults":11,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":4,"eligibilityCriteria":193,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":194,"enrollmentInfo":195,"targetDuration":4,"studyType":22,"phases":197,"briefSummary":199,"conditions":200,"keywords":4,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":46},"100594672","phase-4-assessment-of-oral-caffeine-intake-in-changing-the-severity-of-acute-migraine-attack-using-vas-score-among-patients-attending-headache-and-neurology-outpatients-clinic-of-ainshams-university-hospitals-100594672","NCT07022496","Assessment of Oral Caffeine Intake in Changing the Severity of Acute Migraine Attack Using VAS Score Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals","Assessment of Oral Caffeine Intake in Reducing the Severity of Acute Migraine Attack Among Patients Attending Headache and Neurology Outpatients Clinic of Ainshams University Hospitals: A Randomized Controlled Trial","Inclusion Criteria:\n\nPatients suffering from migraine with aura, migraine without aura, episodic, and chronic migraine according to ICHD-3 diagnosis will be legible for the study.\n\nExclusion Criteria:\n\nPatients who have history of any cardiac dysrhythmia, hypertension, ischemic heart disease, active peptic ulcer disease, inflammatory bowel disease, obsessive compulsive disorder, pregnancy, breast-feeding, renal failure, hepatic failure, sleep disorder, mental retardation, and history of substance abuse that prevent them from cooperating with us during the study Patients who had headache due to: Cluster headache, trigeminal neuralgia, glossopharyngeal neuralgia, headache secondary to trauma, cranial disorder, vascular disorder, infection, or mass lesion, will also be excluded","60 Years",{"count":196,"type":21},120,[198],"PHASE4","Caffeine extracted from green tea to abort acute attack of Migraine",[27,28,30,201,202],"Migraine Headache, With or Without Aura","Migraine, Acute","2025-06-07",{"date":205,"type":38},"2025-06-15",{"date":207,"type":38},"2023-04-26",{"date":209,"type":21},"2025-08",{"name":211,"class":45},"Ain Shams University",{"id":213,"slug":214,"hasResults":11,"nctId":215,"briefTitle":216,"officialTitle":216,"acronym":217,"eligibilityCriteria":218,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":219,"targetDuration":4,"studyType":172,"phases":4,"briefSummary":221,"conditions":222,"keywords":224,"overallStatus":153,"whyStopped":4,"lastUpdateSubmitDate":228,"lastUpdatePostDateStruct":229,"startDateStruct":231,"completionDateStruct":233,"leadSponsor":235,"locationsCount":46},"100588190","high-density-eeg-meg-wearable-eeg-comparison-of-quantitative-electroencephalographic-indicators-as-neurophysiological-markers-of-effectiveness-of-mindfulness-therapy-in-addition-to-standard-treatment-in-patients-with-high-frequency-episodic-migraine-100588190","NCT06938178","High-Density EEG-MEG-wearable EEG: Comparison of Quantitative Electroencephalographic Indicators as Neurophysiological Markers of Effectiveness of Mindfulness Therapy in Addition to Standard Treatment in Patients With High-frequency Episodic Migraine","MindMEEG","Inclusion Criteria:\n\n* Adult patients will be included who fulfil the ICHD-3 criteria \\[8\\] for HFEM, code 1.3-Chronic Migraine (characteristics similar to CM but with a frequency of 8-14 migraine days per month) with stable therapy in the 3 months prior to the start of Mindfulness treatment. If the therapy is changed during the screening visit, the patient will wait 3 months before starting Mindfulness treatment.\n\nExclusion Criteria:\n\n* in the presence of psychiatric comorbidities in the psychotic area, reported in the history or assessed by the clinician\n* if pregnant\n* in the presence of secondary headache comorbidities (e.g. idiopathic intracranial hypertension)\n* if they have undergone symptomatic abuse detoxification at least twice in the previous two years\n* if they have already undergone any kind of treatment with Mindfulness or meditation techniques",{"count":220,"type":21},40,"Recent studies suggest that Mindfulness may be an effective treatment for migraine, reducing the frequency of attacks, depression, anxiety and improving quality of life. However, the pathophysiological mechanisms underlying the effectiveness are not yet fully known. The identification of neurophysiological markers may help to better understand the mechanisms on which Mindfulness acts in migraine sufferers and to develop increasingly targeted and personalized Mindfulness interventions to optimize migraine treatment. The main objective of the study is to identify neurophysiological indicators of effectiveness of Mindfulness treatment in patients with migraine without high-frequency aura with clinically available devices (MEG and hdEEG). Another goal is to recognize the indicators also in the signal acquired with wearable devices in home use (wEEG). Finally, another goal will be to study the relationship between the identified neurophysiological markers and the change in neuropsychological test scores.",[27,28,223],"High Frequency Episodic Migraine",[27,225,226,227],"MEG","Mindfulness","Wearable EEG","2025-04-14",{"date":230,"type":38},"2025-04-22",{"date":232,"type":38},"2024-04-23",{"date":234,"type":21},"2026-06",{"name":186,"class":45}]